Search Results - Stuart C Williamson

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor. by Stuart C Williamson, Anastasia C Hepburn, Laura Wilson, Kelly Coffey, Claudia A Ryan-Munden, Deepali Pal, Hing Y Leung, Craig N Robson, Rakesh Heer

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  2. 2

    Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. by Anastasia C Hepburn, Rajan Veeratterapillay, Stuart C Williamson, Amira El-Sherif, Neha Sahay, Huw D Thomas, Alejandra Mantilla, Robert S Pickard, Craig N Robson, Rakesh Heer

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  3. 3

    Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry

    Published in npj Breast Cancer (2023-08-01)
    Get full text
    Article


  4. 4

    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry

    Published in npj Breast Cancer (2023-09-01)
    Get full text
    Article


  5. 5

    Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models by Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza DeBruin, Simon T. Barry

    Published in npj Breast Cancer (2023-08-01)
    Get full text
    Article


  6. 6

    The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer by Valentina Cutano, Ming Li Chia, Eleanor M. Wigmore, Lorna Hopcroft, Stuart C. Williamson, Amanda L. Christie, Brandon Willis, James Kerr, Jenny Ashforth, Rhys Fox, Sophie D’Arcy, Lauren Bradshaw, Catherine Blaker, Cath Eberlein, Lambert Montava-Garriga, Elza C. de Bruin, Susan E. Critchlow, Kevin M. Brindle, Simon T. Barry, Susana Ros

    Published in npj Breast Cancer (2025-04-01)
    Get full text
    Article


Search Tools: